anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

12,241-12,270 of 319,975

filter-aware
18
The slide highlights the 'me-too' drug development problem in China.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
19
The slide uses a dual-column layout to contrast market drivers (left) with specific regulatory examples (right).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
20
The slide uses a stacked bar chart to show survey responses and a callout box for qualitative expert feedback.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
21
The slide uses stacked bar charts to show clinical trial phases over time, with CAGR annotations.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
22
The slide uses a three-row structure to map strategic pillars to real-world examples and qualitative expert validation.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
23
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
24
The chart shows a clear shift in clinical trial focus toward oncology, increasing from 30% in 2016 to 48% in 2022.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
25
Uses a 'Past vs Future' transformation framework to illustrate strategic shift.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
26
The chart highlights factors directly related to commercial attractiveness in green.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
27
The chart uses a 7-point Likert scale. The top 4 categories are highlighted in green.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
28
The slide uses a list format with icons to categorize qualitative feedback from interviews.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
29
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
30
The slide uses a structured table to map trends to operational/technical complexity and their specific implications.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
31
The slide uses a chronological framework to explain the shift from paper-based to integrated digital platforms in clinical trials.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
32
The chart combines a horizontal bar chart for penetration rates with a stakeholder usage matrix.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
33
Includes bilingual survey methodology notes.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
34
The slide uses a combination of quantitative survey data and qualitative expert quotes to validate the trend towards smart clinical trial formats.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
35
The slide tracks the progression of Chinese regulatory guidelines (CDE) towards patient-centric and remote clinical trial methodologies.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
36
The slide uses a split-layout to contrast positive drivers against negative barriers.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
37
The slide uses a visual bridge to connect the 'Likely'/'Highly Likely' and 'Unlikely'/'Not Possible' segments of the survey to their respective rationales.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
38
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
39
The slide uses a circular flow diagram to represent a reciprocal relationship between two market actors.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
40
Survey data from IQVIA/L.E.K. Consulting (N=56).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
41
The slide uses stacked bar charts to show ranking preferences (Top 1, 2, 3) for destinations and simple bar charts for decision factors.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
42
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
43
The chart displays quarterly deal numbers, showing significant volatility but a clear increase in peak deal activity post-2018.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
44
The slide highlights the trend of international pharma companies licensing innovative assets from Chinese biotech firms.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
45
The slide highlights a strategic shift in MNC R&D presence in China, moving towards collaborative incubation models.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
46
The slide uses a stacked bar chart to represent survey data (N=81) and includes two testimonial quotes from R&D leads.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
47
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit